---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-076521"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:31:20.780624+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q4 revenue $28.8M (+41% YoY), first-ever positive Adj EBITDA $0.5M

## Summary
- Q4 total revenue $28.8M (+41% YoY), gross margin 83% (up 400bps), net loss improved 52% to $4.0M.
- Diagnostic test revenue $25.1M (+46% YoY), volumes 18,000 tests (+23%), average rev per test increased.
- FY2025 total revenue $88.5M, above raised guidance of $84-86M; FY2026 guidance $106-112M (+23% mid-point).
- First-ever positive Adj EBITDA of $0.5M in Q4; FY2025 Adj EBITDA loss $17.5M improved 21% YoY.
- Post-quarter: amended Perceptive term loan to Nov 2028, raised $14.7M via ATM; pro forma cash $33.7M.

## SEC filing metadata
- accession: 0001193125-26-076521
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076521/0001193125-26-076521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076521/bdsx-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-076521
- JSON: https://secwatch.observer/filing/0001193125-26-076521.json
- Plain text: https://secwatch.observer/filing/0001193125-26-076521.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.